Compared to Estimates, Abbott (ABT) Q4 Earnings: A Look at Key Metrics

Core Insights - Abbott reported $10.97 billion in revenue for Q4 2024, a year-over-year increase of 7.2$1.34 compared to $1.19 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of$11.02 billion by 0.45%, while the EPS met the consensus estimate [1] Financial Performance Metrics - U.S. Diagnostics net sales were $1.06 billion, exceeding the average estimate of$1.03 billion, reflecting a 3.4% year-over-year increase [4] - International Diagnostics net sales were $1.47 billion, below the average estimate of$1.54 billion, showing a year-over-year decline of 3.2% [4] - International Nutrition net sales reached $1.20 billion, slightly below the average estimate of$1.21 billion, with a year-over-year increase of 2% [4] - U.S. Nutrition net sales were $928 million, compared to the average estimate of$942.92 million, marking a 7.9% year-over-year increase [4] - Medical Devices - Rhythm Management total net sales were $624 million, slightly above the average estimate of$623.50 million, with a year-over-year increase of 7.2% [4] - Medical Devices - Diabetes Care net sales were $1.86 billion, exceeding the average estimate of$1.82 billion, reflecting a significant year-over-year increase of 20% [4] - Established Pharmaceuticals net sales were $1.27 billion, below the average estimate of$1.31 billion, with a year-over-year increase of 3.8% [4] - Total Diagnostics net sales were $2.52 billion, slightly below the average estimate of$2.57 billion, showing a year-over-year decline of 0.6% [4] - Total Nutrition net sales were $2.13 billion, below the average estimate of$2.16 billion, with a year-over-year increase of 4.5% [4] - Medical Devices - Vascular total net sales were $725 million, exceeding the average estimate of$714.22 million, with a year-over-year increase of 7.1% [4] - Medical Devices - Neuromodulation total net sales were $257 million, slightly above the average estimate of$253.01 million, reflecting a year-over-year increase of 7.1% [4] - Medical Devices - Structural Heart total net sales were $609 million, exceeding the average estimate of$587.72 million, with a year-over-year increase of 22.3% [4] Stock Performance - Abbott's shares returned +1.8% over the past month, compared to the Zacks S&P 500 composite's +2.1% change, with a Zacks Rank 2 (Buy) indicating potential outperformance in the near term [3]